ABSTRACT
INTRODUCTION
6). The unpleasant side effects of these drugs lead to patient non-compliance compounding the 48 growing concerns about the spread of drug resistant strains. G. lamblia evades the host immune 49 system by frequently switching its Variant-specific Surface Proteins, therefore vaccines 50 development has proven to be a challenge. For these reasons, we have undertaken the discovery 51 of alternative antigiardiasis drugs that are not subjects to current resistance mechanisms.
53
To enable high throughput compound library screening (HTS), we have developed a 54 bioluminescence-based assay that monitors the cellular ATP content in G. lamblia trophozoites, 55 which correlates with the viability of the organism (7). We used this assay to identify compounds greatly reduced and, depending on the compound, the clinical trial phase may also be shorter and 66 less costly. We have therefore undertaken to pursue further preclinical studies of a selected set of 67 the newly discovered drugs, triaging compounds that proved inadequate along the way.
69
While the ATP content assay is amenable to high throughput screening, however it requires 70 confirmation by a secondary assay. Specifically, the ATP-dependent luciferase bioluminescence 71 signal would be abolished when a compound inhibits the metabolic activity of the trophozoite,
72
but the organisms might remain viable and resume proliferation upon completion of treatment.
73
High throughput trophozoite enumeration is also limited in scope because it does not reliably Here we report on follow-up studies of drugs discovered by the previously reported HTS 80 campaign (7 hours, tubes were kept at 37 ºC to allow trophozoite attachment to the wall of the glass tube, after 149 which the medium containing the intestine debris was decanted and replaced by fresh medium.
150
Tubes were kept at 37 ºC for another 15 min followed by a second medium replacement, but this 151 time the medium was supplemented with 1mg/mL piperacillin, 1mg/mL moxalactam, 5 μg/mL amoxicillin/clavulanic acid, and 10 μg/mL nalidixic acid. The drugs chosen to be advanced to animal studies exhibited potency against both WB and GS
216
isolates. Riboflavin butyrate (a vitamin B2 derivative used widely in Japan) was selected for 217 further study because it exhibited significant potency in the MLC assay and is known to be a safe 218 natural product, whereas vitamin B12 was excluded because of lack of detectable potency in the 219 MLC assay. In addition, we eliminated some compounds based on documented toxicity data. The 220 animal studies of disulfiram and thiram have been reported earlier, together with structural studies of the enzyme these compounds target, carbamate kinase (13). The remaining 10 222 compounds that were advanced to animal studies are listed in Table 2 . vitro proliferation assay (13).
234
The adult mouse model we used couples infection and treatment to proliferation of cultures 235 harvested from the small intestine and axenized by using an antibiotic cocktail that includes the 236 β-lactamase inhibitor clavulanic acid. This protocol facilitates accurate quantification of the 237 results as we discussed earlier (13). We adopted a triage procedure to screen all 10 compounds 238 for efficacy in the mouse model by first using relatively high drug doses (5 mg/day) with two can be seen in Table 3 , three of the drugs were highly toxic at 5 mg/day dose and necessitated 243 euthanizing the mice (deserpidine, nifuroxime, nitarsone). Nithiamide was lethal in three mice whereas the remaining seven mice appeared unaffected. As a precaution, these seven mice were 245 treated with reduced dose of 1 mg/day after the first day. The mice studies eliminated the highly toxic drugs, deserpidine, nifuroxime, and nitarsone.
275
Nithiamide was also eliminated because of its lethal effect at high dose (5 mg) and poor efficacy 
292
Carbadox showed only a few trophozoites left and these exhibited unhealthy morphology and
293
were unable to proliferate ( were tested over 4-day treatments, 0.6, 12, and 120 mg/Kg. As shown in Table 5 patients, for example by reducing compound transport across the intestinal epithelial cell burrier.
406
The drug development process would benefit from accompanying structural studies that reveal limited, it is obvious that the inserted residues must alter the loops structure, which in turn might 420 affect the conformations of adjacent regions. Thus, the active site structural differences provide 421 opportunities for developing fumagillin derivatives that inhibit the Giardia MetAP2 selectively 422 and do not interfere with the human MetAP2.
Conclusions

425
The preclinical studies reported here have shown that fumagillin is a promising efficacious 426 antigiardiasis drug. Fumagillin exhibits potency against both metronidazole-sensitive and 427 metronidazole-resistant G. lamblia isolates, hence it offers an alternative treatment for giardiasis 428 that is refractive to standard care drugs. Moreover, it would be worthwhile to investigate whether 429 combining fumagillin with standard care drugs prevents or slows down the spread of resistance.
430
The comparative three-dimensional model suggests that the key residues that surround the bound 
524
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth.
525
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